Pulmonary-Allergy Drugs Advisory Committee Meeting

Pulmonary-Allergy Drugs Advisory Committee Meeting Committee Meeting : March 7, 2013 from 8:00 a.m. to 5:00 p.m. Agenda: The committee will discuss the new drug application (NDA) 204275 for fluticasone furoate and vilanterol dry powder inhaler (proposed tradename BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease.